<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862962</url>
  </required_header>
  <id_info>
    <org_study_id>SIL-30231-IV-20(1)</org_study_id>
    <nct_id>NCT04862962</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia</brief_title>
  <acronym>TREZETE</acronym>
  <official_title>Retrospective Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin / Ezetimibe as a Treatment for Patients With Dyslipidaemia in Usual Medical Practice.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective, analytical, longitudinal, multicenter study to evaluate the safety of the&#xD;
      fixed-dose combination of rosuvastatin / ezetimibe as treatment for patients with&#xD;
      dyslipidemia in routine medical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety of the fixed-dose combination of rosuvastatin / ezetimibe in subjects&#xD;
      older than 18 years of age (gender indistinct) with dyslipidemia who at the discretion have&#xD;
      been candidates for treatment with the combination. For the safety analysis, all the research&#xD;
      subjects who have taken rosuvastatin / ezetimibe will be considered. The information recorded&#xD;
      by the treating physicians in the file will be reviewed and within the case report format&#xD;
      (CRF) of all adverse events that occur in the study. The terms originally used in the case&#xD;
      report format by the investigators to identify adverse events (AE) will be coded in the&#xD;
      analysis stage of Results using the current MEdDRA dictionary. The incidence of AE will be&#xD;
      synthesized such as the frequency count and percentage of research subjects with events&#xD;
      adverse by organ / system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events presented</measure>
    <time_frame>2 months</time_frame>
    <description>Describe the frequency and intensity of adverse events presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average difference in lipid profile values</measure>
    <time_frame>Baseline, 2 months</time_frame>
    <description>Evaluate the average difference in lipid profile values between at least 2 measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>2 months</time_frame>
    <description>To assess adherence to treatment with rosuvastatin / ezetimibe fixed-dose combination by pill count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant reduction in LDL cholesterol</measure>
    <time_frame>2 months</time_frame>
    <description>To assess the proportion of subjects who achieved a significant reduction in LDL cholesterol at each concentration of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who met established goals according to cardiovascular risk</measure>
    <time_frame>2 months</time_frame>
    <description>To identify the percentage of patients who met the established goals according to cardiovascular risk determined by the European Society of Cardiology (ESC) and / or American Heart Association (AHA) / American College of Cardiology (ACC) recommendations.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Group A: Rosuvastatin /Ezetimibe fixed dose (TREZETE®)</arm_group_label>
    <description>Rosuvastatin /Ezetimibe fixed dose (TREZETE®) Pharmaceutical Form: Tablets Dosage: 10 mg / 10 mg or 20 mg / 10 mg Administration way: Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose</intervention_name>
    <description>Oral Tablets 10 mg/10 mg or 20 mg/10 mg</description>
    <arm_group_label>Group A: Rosuvastatin /Ezetimibe fixed dose (TREZETE®)</arm_group_label>
    <other_name>(TREZETE®)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects over 18 years of age (gender indistinct) with dyslipidemia who, at the discretion&#xD;
        of thetreating physician have been candidates for treatment with the fixed-dose combination&#xD;
        of rosuvastatin-ezetimibe.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years of age.&#xD;
&#xD;
          -  Diagnosis of dyslipidemia.&#xD;
&#xD;
          -  That treatment with the fixed-dose combination of rosuvastatin / ezetimibe is&#xD;
             documented.&#xD;
&#xD;
          -  Have security questioning on at least two occasions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who has taken any other statins, fibrates, bile acid sequestrants, niacin (&gt;&#xD;
             500 mg) or inhibitors of PCSK9 concomitantly during treatment with rosuvastatin /&#xD;
             ezetimibe.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Rodriguez Saldaña, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resultados Médicos, desarrollo e Investigación</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco G Padilla Padilla, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernesto G Cardona Muñoz, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Cardona Müller, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcos Ibarra Flores, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiólogos Certificados S.C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José A Estrada Suarez, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge A González, PhD</last_name>
    <phone>5254883785</phone>
    <phone_ext>3761</phone_ext>
    <email>jogonzalez@silanes.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yulia G Romero-Antonio, B.S.</last_name>
    <phone>5554883700</phone>
    <phone_ext>3777</phone_ext>
    <email>yromero@silanes.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratorio Silanes, S.A. de C.V.</name>
      <address>
        <city>Mexico City</city>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Jorge A Gonzalez, PhD</last_name>
      <phone>+5254883785</phone>
      <phone_ext>3761</phone_ext>
      <email>jogonzalez@silanes.com.mx</email>
    </contact>
    <contact_backup>
      <last_name>Yulia Romero-Antonio, B.S.</last_name>
      <phone>5554883700</phone>
      <phone_ext>3777</phone_ext>
      <email>yromero@silanes.com.mx</email>
    </contact_backup>
    <investigator>
      <last_name>Joel Rodríguez Saldaña, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco G Padilla Padilla, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ernesto G Cardona Muñoz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Cardona Müller., M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcos Ibarra Flores, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José A Estrada Suarez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Garcia-Garcia G, Aviles-Gomez R, Luquin-Arellano VH, Padilla-Ochoa R, Lepe-Murillo L, Ibarra-Hernandez M, Briseño-Renteria G. Cardiovascular risk factors in the Mexican population. Ren Fail. 2006;28(8):677-87. Review.</citation>
    <PMID>17162426</PMID>
  </reference>
  <reference>
    <citation>Roth GA, Fihn SD, Mokdad AH, Aekplakorn W, Hasegawa T, Lim SS. High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. Bull World Health Organ. 2011 Feb 1;89(2):92-101. doi: 10.2471/BLT.10.079947. Epub 2010 Sep 3.</citation>
    <PMID>21346920</PMID>
  </reference>
  <reference>
    <citation>Escobedo-de la Peña J, de Jesús-Pérez R, Schargrodsky H, Champagne B. [Prevalence of dyslipidemias in Mexico city and Its relation to other cardiovascular risk factors. Results from the CARMELA study]. Gac Med Mex. 2014 Mar-Apr;150(2):128-36. Spanish.</citation>
    <PMID>24603993</PMID>
  </reference>
  <reference>
    <citation>Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018 Dec;15(12):757-769. doi: 10.1038/s41569-018-0098-5. Review.</citation>
    <PMID>30375494</PMID>
  </reference>
  <reference>
    <citation>Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 2012;6:17-33. doi: 10.4137/CMC.S4324. Epub 2012 Feb 1.</citation>
    <PMID>22442638</PMID>
  </reference>
  <reference>
    <citation>Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther. 2004 Sep;26(9):1368-87. Review.</citation>
    <PMID>15531000</PMID>
  </reference>
  <reference>
    <citation>Rubba P, Marotta G, Gentile M. Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc Health Risk Manag. 2009;5(1):343-52. Epub 2009 Apr 8. Review.</citation>
    <PMID>19436657</PMID>
  </reference>
  <reference>
    <citation>Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812. Review.</citation>
    <PMID>21267417</PMID>
  </reference>
  <reference>
    <citation>Battaggia A, Donzelli A, Font M, Molteni D, Galvano A. Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015 Apr 27;10(4):e0124587. doi: 10.1371/journal.pone.0124587. eCollection 2015. Review.</citation>
    <PMID>25915909</PMID>
  </reference>
  <reference>
    <citation>Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E; EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007 Mar 1;99(5):673-80. Epub 2007 Jan 4.</citation>
    <PMID>17317370</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemias</keyword>
  <keyword>Combine therapy</keyword>
  <keyword>Lower Cholesterol</keyword>
  <keyword>Lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

